Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis

Context Xiaoyaosan decoction (XYS), a classical Traditional Chinese Medicine (TCM) formula is used to treat liver fibrosis in clinics. Objective This study explores defined compound combinations from XYS decoction to treat liver fibrosis. Materials and methods Network pharmacology combined with tran...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuan Zhou, Rong Wu, Fei-fei Cai, Wen-Jun Zhou, Yi-Yu Lu, Hui Zhang, Qi-Long Chen, Ming-Yu Sun, Shi-Bing Su
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	xiaoyaosan decoction llaaf anti-liver fibrotic effect Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/de0df60900da41b4879357df7764c9d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de0df60900da41b4879357df7764c9d8
record_format	dspace
spelling	oai:doaj.org-article:de0df60900da41b4879357df7764c9d82021-11-26T11:19:47ZDevelopment of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis1388-02091744-511610.1080/13880209.2021.1999275https://doaj.org/article/de0df60900da41b4879357df7764c9d82021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/13880209.2021.1999275https://doaj.org/toc/1388-0209https://doaj.org/toc/1744-5116Context Xiaoyaosan decoction (XYS), a classical Traditional Chinese Medicine (TCM) formula is used to treat liver fibrosis in clinics. Objective This study explores defined compound combinations from XYS decoction to treat liver fibrosis. Materials and methods Network pharmacology combined with transcriptomics analysis was used to analyze the XYS decoction and liver depression and spleen deficiency syndrome liver fibrosis. From the constructed XYS-Syndrome-liver fibrosis network, the top 10 active formulas were developed by topological analysis according to network stability. The most active formula was determined by in vitro study. The anti-fibrosis effect was evaluated by in vitro and in vivo studies. Results According to the network XYS-Syndrome-liver fibrosis network, 8 key compounds and 255 combinations were predicted from in XYS. Luteolin, licochalcone A, aloe-emodin and acacetin formula (LLAAF) had a synergistic effect on the proliferation inhibition of hepatic stellate cells compared to individual compounds alone. The treatment of XYS and LLAAF showed a similar anti-liver fibrotic effect that reduced histopathological changes of liver fibrosis, Hyp content and levels of α-SMA and collagen I in CCl4-induced liver fibrosis in rats. Transcriptomics analysis revealed LLAAF regulated PI3K-Akt, AMPK, FoxO, Jak-STAT3, P53, cell cycle, focal adhesion, and PPAR signalling. Furthermore, LLAAF was confirmed to regulate Jak-STAT and PI3K-Akt-FoxO signalling in vitro and in vivo. Conclusions This study developed a novel anti-liver formula LLAAF from XYS, and demonstrated its anti-liver fibrotic activity which may be involved in the regulation of Jak-STAT and PI3K-Akt-FoxO signalling.Yuan ZhouRong WuFei-fei CaiWen-Jun ZhouYi-Yu LuHui ZhangQi-Long ChenMing-Yu SunShi-Bing SuTaylor & Francis Grouparticlexiaoyaosan decoctionllaafanti-liver fibrotic effectTherapeutics. PharmacologyRM1-950ENPharmaceutical Biology, Vol 59, Iss 1, Pp 1594-1606 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	xiaoyaosan decoction llaaf anti-liver fibrotic effect Therapeutics. Pharmacology RM1-950
spellingShingle	xiaoyaosan decoction llaaf anti-liver fibrotic effect Therapeutics. Pharmacology RM1-950 Yuan Zhou Rong Wu Fei-fei Cai Wen-Jun Zhou Yi-Yu Lu Hui Zhang Qi-Long Chen Ming-Yu Sun Shi-Bing Su Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
description	Context Xiaoyaosan decoction (XYS), a classical Traditional Chinese Medicine (TCM) formula is used to treat liver fibrosis in clinics. Objective This study explores defined compound combinations from XYS decoction to treat liver fibrosis. Materials and methods Network pharmacology combined with transcriptomics analysis was used to analyze the XYS decoction and liver depression and spleen deficiency syndrome liver fibrosis. From the constructed XYS-Syndrome-liver fibrosis network, the top 10 active formulas were developed by topological analysis according to network stability. The most active formula was determined by in vitro study. The anti-fibrosis effect was evaluated by in vitro and in vivo studies. Results According to the network XYS-Syndrome-liver fibrosis network, 8 key compounds and 255 combinations were predicted from in XYS. Luteolin, licochalcone A, aloe-emodin and acacetin formula (LLAAF) had a synergistic effect on the proliferation inhibition of hepatic stellate cells compared to individual compounds alone. The treatment of XYS and LLAAF showed a similar anti-liver fibrotic effect that reduced histopathological changes of liver fibrosis, Hyp content and levels of α-SMA and collagen I in CCl4-induced liver fibrosis in rats. Transcriptomics analysis revealed LLAAF regulated PI3K-Akt, AMPK, FoxO, Jak-STAT3, P53, cell cycle, focal adhesion, and PPAR signalling. Furthermore, LLAAF was confirmed to regulate Jak-STAT and PI3K-Akt-FoxO signalling in vitro and in vivo. Conclusions This study developed a novel anti-liver formula LLAAF from XYS, and demonstrated its anti-liver fibrotic activity which may be involved in the regulation of Jak-STAT and PI3K-Akt-FoxO signalling.
format	article
author	Yuan Zhou Rong Wu Fei-fei Cai Wen-Jun Zhou Yi-Yu Lu Hui Zhang Qi-Long Chen Ming-Yu Sun Shi-Bing Su
author_facet	Yuan Zhou Rong Wu Fei-fei Cai Wen-Jun Zhou Yi-Yu Lu Hui Zhang Qi-Long Chen Ming-Yu Sun Shi-Bing Su
author_sort	Yuan Zhou
title	Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
title_short	Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
title_full	Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
title_fullStr	Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
title_full_unstemmed	Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
title_sort	development of a novel anti-liver fibrosis formula with luteolin, licochalcone a, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/de0df60900da41b4879357df7764c9d8
work_keys_str_mv	AT yuanzhou developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT rongwu developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT feifeicai developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT wenjunzhou developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT yiyulu developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT huizhang developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT qilongchen developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT mingyusun developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis AT shibingsu developmentofanovelantiliverfibrosisformulawithluteolinlicochalconeaaloeemodinandacacetinbynetworkpharmacologyandtranscriptomicsanalysis
_version_	1718409565894082560

Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis

Ejemplares similares